Realizing the promise of personalized medicines for cancer
Clovis Oncology (NASDAQ: CLVS) is developing targeted cancer therapies in combination with companion diagnostics to ensure that the right drug gets to the right patients. The company achieved FDA approval for Rubraca (rucaparib) in 2016 to treat women with advanced ovarian cancer whose tumors have a BRCA mutation. Clovis completed its IPO in 2011.